The gut microbiome and liver cancer: mechanisms and clinical translation

Gut Microbiota Promotes Obesity-Associated Liver Cancer through PGE 2 -Mediated Suppression of Antitumor Immunity

(2017) Tze Mun Loo et al.   Cancer Discovery

Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota

(2017) Da Zhou et al.   Scientific Reports

HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients

(2016) J. S. Bajaj et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Bile acids regulate intestinal cell proliferation by modulating EGFR and FXR signaling

(2016) Avafia Y. Dossa et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

DSS colitis promotes tumorigenesis and fibrogenesis in a choline-deficient high-fat diet-induced NASH mouse model

(2016) Koichi Achiwa et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Cirrhosis related functionality characteristic of the fecal microbiota as revealed by a metaproteomic approach

(2016) Xiao Wei et al.   BMC GASTROENTEROLOGY

Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk

(2016) Weifei Zhu et al.   CELL

Alcoholic Liver Disease

(2016) Kartik Joshi et al.   Clinics in Liver Disease

Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis

(2016) Long-Xian Lv et al.   ENVIRONMENTAL MICROBIOLOGY

Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis

(2016) Asem Elfert et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach

(2016) Federica Del Chierico et al.   HEPATOLOGY

The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota

(2016) Jérôme Boursier et al.   HEPATOLOGY

Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats

(2016) María Úbeda et al.   JOURNAL OF HEPATOLOGY

Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure

(2016) Rajeshwar P. Mookerjee et al.   JOURNAL OF HEPATOLOGY

Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor

(2016) Veit Rothhammer et al.   NATURE MEDICINE

CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands

(2016) Bruno Lamas et al.   NATURE MEDICINE

Signals from the gut microbiota to distant organs in physiology and disease

(2016) Bjoern O Schroeder et al.   NATURE MEDICINE

The role of the gut microbiota in NAFLD

(2016) Christopher Leung et al.   Nature Reviews Gastroenterology & Hepatology

Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice

(2016) Jun Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease

(2016) H. Chu et al.   SCIENCE

Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease

(2016) Marialena Mouzaki et al.   PLoS One

Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology

(2016) Yanfei Chen et al.   Scientific Reports

The FXR Agonist Obeticholic Acid Prevents Gut Barrier Dysfunction and Bacterial Translocation in Cholestatic Rats

(2015) Len Verbeke et al.   AMERICAN JOURNAL OF PATHOLOGY

Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice

(2015) Amit G. Singal et al.   Clinical Gastroenterology and Hepatology

Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice

(2015) Magdalena Mazagova et al.   FASEB JOURNAL

Supplementation of Saturated Long-Chain Fatty Acids Maintains Intestinal Eubiosis and Reduces Ethanol-induced Liver Injury in Mice

(2015) Peng Chen et al.   GASTROENTEROLOGY

Gut–Liver Axis in Alcoholic Liver Disease

(2015) Gyongyi Szabo   GASTROENTEROLOGY

Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis

(2015) James H. Tabibian et al.   HEPATOLOGY

Dysbiosis-induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice

(2015) Peng Chen et al.   HEPATOLOGY

Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy

(2015) Jasmohan S. Bajaj et al.   HEPATOLOGY

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Decompensated cirrhosis and microbiome interpretation

(2015) Jasmohan S. Bajaj et al.   NATURE

Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota

(2015) Han-Hsuan Chou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

(2015) A. Sivan et al.   SCIENCE

A gut-vascular barrier controls the systemic dissemination of bacteria

(2015) Ilaria Spadoni et al.   SCIENCE

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

(2015) M. Vetizou et al.   SCIENCE

Nutritional Keys for Intestinal Barrier Modulation

(2015) Stefania De Santis et al.   Frontiers in Immunology

Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis

(2014) A. Alisi et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Probiotic VSL#3 Reduces Liver Disease Severity and Hospitalization in Patients With Cirrhosis: A Randomized, Controlled Trial

(2014) Radha K. Dhiman et al.   GASTROENTEROLOGY

Interactions Between the Intestinal Microbiome and Liver Diseases

(2014) Bernd Schnabl et al.   GASTROENTEROLOGY

Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation

(2014) Chiara Degirolamo et al.   HEPATOLOGY

Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease

(2014) Changtao Jiang et al.   JOURNAL OF CLINICAL INVESTIGATION

Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013

(2014) Rajiv Jalan et al.   JOURNAL OF HEPATOLOGY

Alterations of the human gut microbiome in liver cirrhosis

(2014) Nan Qin et al.   NATURE

Gut microbiota–generated metabolites in animal health and disease

(2014) Won-Jae Lee et al.   Nature Chemical Biology

Impact of Rifaximin on the Frequency and Characteristics of Spontaneous Bacterial Peritonitis in Patients with Liver Cirrhosis and Ascites

(2014) Philipp Lutz et al.   PLoS One

Gastrointestinal dysfunction in liver cirrhosis

(2014) Evangelos Kalaitzakis   WORLD JOURNAL OF GASTROENTEROLOGY

Targeting the Gut–Liver Axis in Cirrhosis: Antibiotics and Non-Selective β-Blockers

(2013) Bjørn S. Madsen et al.   ADVANCES IN THERAPY

A Randomized, Double-Blind, Controlled Trial Comparing Rifaximin Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy

(2013) Barjesh Chander Sharma et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Intestinal microbiota in patients with nonalcoholic fatty liver disease

(2013) Marialena Mouzaki et al.   HEPATOLOGY

Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats

(2013) Len Verbeke et al.   HEPATOLOGY

Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice

(2013) Samuele De Minicis et al.   HEPATOLOGY

Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis

(2013) Steven M. Opal et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome

(2013) Shin Yoshimoto et al.   NATURE

Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis

(2013) Robert A Koeth et al.   NATURE MEDICINE

NAFLD, NASH and liver cancer

(2013) Gregory A. Michelotti et al.   Nature Reviews Gastroenterology & Hepatology

Bile acid receptors as targets for drug development

(2013) Frank G. Schaap et al.   Nature Reviews Gastroenterology & Hepatology

Fecal Microbiota Transplantation — An Old Therapy Comes of Age

(2013) Ciarán P. Kelly   NEW ENGLAND JOURNAL OF MEDICINE

Intestinal Microbial Metabolism of Phosphatidylcholine and Cardiovascular Risk

(2013) W.H. Wilson Tang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile

(2013) Els van Nood et al.   NEW ENGLAND JOURNAL OF MEDICINE

Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment

(2013) N. Iida et al.   SCIENCE

The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide

(2013) S. Viaud et al.   SCIENCE

VSL#3 probiotic modifies mucosal microbial composition but does not reduce colitis-associated colorectal cancer

(2013) Janelle C. Arthur et al.   Scientific Reports

Toll-like receptor 4 signaling promotes epithelial-mesenchymal transition in human hepatocellular carcinoma induced by lipopolysaccharide

(2012) Ying-Ying Jing et al.   BMC Medicine

Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4

(2012) Dianne H. Dapito et al.   CANCER CELL

Effect of Long-term Propranolol Treatment on Hepatocellular Carcinoma Incidence in Patients with HCV-Associated Cirrhosis

(2012) G. Nkontchou et al.   Cancer Prevention Research

Rifaximin Improves Systemic Hemodynamics and Renal Function in Patients With Alcohol-Related Cirrhosis and Ascites

(2012) Georgios N. Kalambokis et al.   Clinical Gastroenterology and Hepatology

High Prevalence of Antibiotic-Resistant Bacterial Infections Among Patients With Cirrhosis at a US Liver Center

(2012) Puneeta Tandon et al.   Clinical Gastroenterology and Hepatology

Transfer of Intestinal Microbiota From Lean Donors Increases Insulin Sensitivity in Individuals With Metabolic Syndrome

(2012) Anne Vrieze et al.   GASTROENTEROLOGY

Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice

(2012) Dewei Ye et al.   GUT

Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH

(2012) Lixin Zhu et al.   HEPATOLOGY

Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis

(2012) Jiannis Vlachogiannakos et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

964 THE FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) INCREASES PLASMA FGF-19 CONCENTRATIONS AND DECREASES BILE ACID SYNTHESIS IN PRIMARY BILIARY CIRRHOSIS (PBC)

(2012) H.-U. Marschall et al.   JOURNAL OF HEPATOLOGY

Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats

(2012) Hui-Lu Zhang et al.   JOURNAL OF HEPATOLOGY

Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease

(2012) Derrick E. Fouts et al.   JOURNAL OF HEPATOLOGY

Functional interactions between the gut microbiota and host metabolism

(2012) Valentina Tremaroli et al.   NATURE

Modulation of intestinal barrier by intestinal microbiota: Pathological and therapeutic implications

(2012) Jane M.M. Natividad et al.   PHARMACOLOGICAL RESEARCH

Regulated Virulence Controls the Ability of a Pathogen to Compete with the Gut Microbiota

(2012) N. Kamada et al.   SCIENCE

Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists

(2011) Francesco Peri et al.   BIOTECHNOLOGY ADVANCES

Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies

(2011) Amisha Barochia et al.   Expert Opinion on Drug Metabolism & Toxicology

Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets

(2011) Bin Gao et al.   GASTROENTEROLOGY

Selective Activation of Nuclear Bile Acid Receptor FXR in the Intestine Protects Mice Against Cholestasis

(2011) Salvatore Modica et al.   GASTROENTEROLOGY

Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease

(2011) R. M. Gadaleta et al.   GUT

Characterization of fecal microbial communities in patients with liver cirrhosis

(2011) Yanfei Chen et al.   HEPATOLOGY

Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: A prospective study

(2011) Javier Fernández et al.   HEPATOLOGY

DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH

(2011) Erwin Gäbele et al.   JOURNAL OF HEPATOLOGY

Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice

(2011) Qiang Zhu et al.   JOURNAL OF HEPATOLOGY

Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease

(2011) Zeneng Wang et al.   NATURE

Hepatocellular Carcinoma

(2011) Hashem B. El-Serag   NEW ENGLAND JOURNAL OF MEDICINE

Pattern Recognition Receptors and Inflammation

(2010) Osamu Takeuchi et al.   CELL

A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis*

(2010) Todd W. Rice et al.   CRITICAL CARE MEDICINE

Gut microbiota and probiotics in chronic liver diseases

(2010) Claudia Cesaro et al.   DIGESTIVE AND LIVER DISEASE

Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis

(2010) Pablo Bellot et al.   HEPATOLOGY

Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents

(2010) Le-Xing Yu et al.   HEPATOLOGY

The role of intestinal endotoxin in liver injury: A long and evolving history

(2010) James P. Nolan   HEPATOLOGY

Enteric dysbiosis associated with a mouse model of alcoholic liver disease

(2010) Arthur W. Yan et al.   HEPATOLOGY

Genetic Diversity and Virulence Profiles of Escherichia coli Isolates Causing Spontaneous Bacterial Peritonitis and Bacteremia in Patients with Cirrhosis

(2010) F. Bert et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis

(2010) Christian J Steib et al.   LABORATORY INVESTIGATION

Rifaximin Treatment in Hepatic Encephalopathy

(2010) Nathan M. Bass et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Etiology of Hepatocellular Carcinoma and Consequences for Treatment

(2010) A. J. Sanyal et al.   ONCOLOGIST

Toll-like Receptor 4 and Hepatic Fibrogenesis

(2010) Jean-Philippe Pradere et al.   SEMINARS IN LIVER DISEASE

Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis

(2009) J. VLACHOGIANNAKOS et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Review article: the management of hepatocellular carcinoma

(2009) R. CABRERA et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Oral Propranolol Decreases Intestinal Permeability in Patients With Cirrhosis: Another Protective Mechanism Against Bleeding?

(2009) Marco Senzolo et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases

(2009) Hoonmo L Koo et al.   CURRENT OPINION IN GASTROENTEROLOGY

Norfloxacin Modulates the Inflammatory Response and Directly Affects Neutrophils in Patients With Decompensated Cirrhosis

(2009) Pedro Zapater et al.   GASTROENTEROLOGY

Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease

(2009) Luca Miele et al.   HEPATOLOGY

Glycolipids and Benzylammonium Lipids as Novel Antisepsis Agents: Synthesis and Biological Characterization

(2009) Matteo Piazza et al.   JOURNAL OF MEDICINAL CHEMISTRY

β-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis

(2009) Marco Senzolo et al.   LIVER INTERNATIONAL

Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog

(2009) K. Machida et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hepatitis C Virus and Alcohol

(2009) Larry Siu et al.   SEMINARS IN LIVER DISEASE

Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice

(2008) Mathieu Membrez et al.   FASEB JOURNAL

The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88

(2008) Istvan Hritz et al.   HEPATOLOGY

Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis

(2008) Rubén Francés et al.   HEPATOLOGY

A core gut microbiome in obese and lean twins

(2008) Peter J. Turnbaugh et al.   NATURE

Targeting bile-acid signalling for metabolic diseases

(2008) Charles Thomas et al.   NATURE REVIEWS DRUG DISCOVERY